Clinical Pharmacology and Therapeutics 1991: Vol 49 Index

17 Pages·1991·3.9 MB·English

LINICAL
HARMACOLOGY
& "THERAPEUTICS
EDITOR Arthur Hull Hayes, Jr., MD
Marcus M. Reidenberg, MD Thomas K. Henthorn, MD
Jordan L. Holtzman, MD, PhD
EDITOR EMERITUS Leonard Horowitz, MD
Aryeh Hurwitz, MD
Walter Modell, MD
Harold D. Itskovitz, MD
William J. Jusko, PhD
ASSOCIATE EDITORS
Anthony Kales, MD
Arthur J. Atkinson, Jr., MD
Paul D. Stolley, MD, MPH Werner Kalow, MD
Stanley A. Kaplan, PhD
Raymond L. Woosley, MD, PhD
Louis Lasagna, MD
Louis Lemberger, PhD, MD
ASSISTANT EDITOR Juan J. L. Lertora, MD, PhD
B. Robert Meyer, MD Gerhard Levy, PharmD
David T. Lowenthal, MD, PhD
MANAGING EDITOR Carl V. Manion, MD
June Reidenberg Urs A. Meyer, MD
Jerry R. Mitchell, MD, PhD
EDITORIAL BOARD Arno G. Motulsky, MD
Darrell R. Abernethy, MD, PhD Allen H. Neims, MD, PhD
Alvito P. Alvares, PhD Edward B. Nelson, MD, PhD
Matthew M. Ames, PhD Harold C. Neu, MD
Fred Y. Aoki, MD David W. Nierenberg, MD
Danie! L., Azarnoft, MD Alan S. Nies, MD
William M. Bennett, MD George D. Olsen, MD
Leif Bertilsson, PhD Carl C. Peck, MD
Joseph R. Bianchine, MD, PhD William Z. Potter, MD, PhD
Thorir D. Bjornsson, MD David Robertson, MD
Terrence F. Blaschke, MD Jerome J. Schentag, PharmD
Saul S. Bloomfield, MD Edward M. Sellers, MD, PhD, FRCP(C)
Paula Botstein, MD Lewis B. Sheiner, MD
R. A. Branch, MD Daniel S. Sitar, PhD
D. Craig Brater, MD Folke Sjoqvist, MD
Alastair Breckenridge, MSc, MD Cedric M. Smith, MD
Edward A. Carr, Jr., MD Reynold Spector, MD
David M. Cocchetto, PhD Stephen P. Spielberg, MD, PhD, FRCP(C)
Robert J. Cody, Jr., MD Donald R. Stanski, MD
Allan H. Conney, PhD Robert Temple, MD
Joann L. Data, MD, PhD Leroy D. Vandam, MD
Colin Dollery, MB, ChB, BSc Elliot S. Vese!!, MD
Edward F. Domino, MD Robert E. Vestal, MD
Dennis E. Drayer, PhD John G. Wagner, PhD
Toby R. Engel, MD Miles M. Weinberger, MD
Alvan R. Feinstein, MD Richard Weinshilboum, MD
Kathleen Giacomini, PhD William B. White, MD
Milo Gibaldi, PhD Thomas L. Whitsett, MD
Linda E. Gustavson, PhD Grant R. Wilkinson, PhD
Perry V. Halushka, MD, PhD Alastair J.J. Wood, MB, ChB
VOLUME 49, JANUARY-JUNE 1991
MOSBY-YEAR BOOK, INC., ST. LOUIS
Volume 49
Copyright © 1991 by
Mosby-— Year Book, Inc.
All rights reserved
Printed in the United States of America
Index to volume 49
Author index
A Bléchl-Daum B, Schuller-Petrovic S, Wolzt M, Kom A, Bohler K,
Eichler H-G. Primary defect in a-adrenergic responsiveness in pa-
Abels J (see Ermens et al). 1991;49:385-93 tients with varicose veins. 1991;49:49-52
Abraham PA (see Moser et al). 1991;49:322-9 Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison
Albgge K (see Clasen et al). 1991;49:624-31 NJ, Schentag JJ. Effect of fluconazole on the disposition of
Amouretti M (see Demotes-Mainard et al). 1991;49:263-9 phenytoin. 1991;49:420-5
Ando R( see Szefler et al). 1991;49:59-68 BGhler K (see Bléchl-Daum et al). 1991;49:49-52
Angelin B (see Hedman et al). 1991;49:256-62 Borkowski KR (see Luthra et al). 1991;49:355-61
Aoyagi N (see Kaniwa et al). 1991;49:641-7 Boyle DA (see Blanchett et al). 1991;49:449-56
Arvidsson A (see Hedman et al). 1991;49:256-62 Brachfeld N (see Moser et al). 1991;49:322-9
Ash CL (see Burton et al). 1991;49:685-94 Brater DC (see Fredrick et al). 1991;49:241-7
Atkinson AJ Jr (see Ehrenpreis et al). 1991;49:632-40 Brodie CL (see Shepherd et al). 1991;49:69-77
Aubin F (see Berlin et al). 1991;49:362-9 Brgsen K (see Clasen et al). 1991;49:624-31
——sen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the
sparteine-debrisoquin oxidation polymorphism, in the metabolism
of imipramine. 1991;49:609-17
sen K (see Skjelbo et al). 1991;49:18-23
Bachert P (see Port et al). 1991;49:497-505
Brown Y (see Wiest et al). 1991;49:550-7
Bailey DG, Carruthers SG. Interaction between oral verapamil and B-
Brundage RC (see Wiest et al). 1991;49:550-7
blockers during submaximal exercise: relevance of ancillary prop-
Brunner-Ferber F (see Bauer et al). 1991;49:658-64
erties. 1991;49:370-6
(see Buclin et al). 1991;49:665-73
Barbhaiya RH (see Knupp et al). 1991;49:523-35 Buclin T, Biollaz J, Lippa EA, Brunner-Ferber F, van Melle G,
Bauer K, Brunner-Ferber F, Distlerath LM, Lippa A, Binkowitz B, Till Munafo A, Clineschmidt C, Schelling JL. Absence of metabolic
P, Kaik G. Assessment of systemic effects of different ophthalmic
effects of the topical carbonic anhydrase inhibitors MK-927 and
B-blockers in healthy volunteers. 1991;49:658-64
sezolamide during two-week ocular administration to normal sub-
Beaver WT (see Forbes et al). 1991;49:674-84
jects. 1991;49:665-73
Beck O (see Hedman et al). 1991;49:256-62 Burton ME, Ash CL, Hill DP Jr, Hardy T, Shepherd MD, Vasko MR.
Begaud B (see Demotes-Mainard et al). 1991;49:263-9 A controlled trial of the cost benefit of computerized bayesian
Benitez J. Preparing a personal formulary as part of a course in clinical
aminoglycoside administratior.. 1991;49:685-94
pharmacology. 1991;49:606-8 (Commentary)
Bennett WM (see Moser et al). 1991;49:322-9 Cc
Benowitz NL, Jacob P III, Denaro C, Jenkins R. Stable isotope studies
of nicotine kinetics and bioavailability. 1991;49:270-7 Calabresi L (see Pazzucconi et al). 1991;49:278-84
Berlin I, Crespo-Laumonnier B, Coumot A, Landault C, Aubin F, Camara DS (see Dunn et al). 1991;49:536-49
Legrand JC, Puech AJ. The «2-adrenergic receptor antagonist yo- Carruthers SG (see Bailey and Carruthers). 1991;49:370-6
himbine inhibits epinephrine-induced platelet aggregation in —— (see Luthra et al). 1991;49:355-61
healthy subjects. 1991;49:362-9 Chan D (see Hui et al). 1991;49:457-67
Bertino JS Jr (see Nafziger and Bertino). 1991;49:596 (Letter) Cicutto LC (see Szefler et al). 1991;49:59-68
Bevan DR (see Donati et al). 1991;49:515-22 Clasen K, Madsen L, Brdsen K, Albgge K, Misfeldt S, Gram LF. Spar-
Binkowitz B (see Bauer et al). 1991;49:658-64 teine and mephenytoin oxidation: genetic polymorphisms in East
Biollaz J (see Buclin et al). 1991;49:665-73 and West Greenland. 1991;49:624-31
Bixler EO (see Kales et al). 1991;49:468-76 Clineschmidt C (see Buclin et al). 1991;49:665-73
Blair IA (see Turgeon et al). 1991;49:488-96 Corder CN (see Blanchett et al). 1991;49:449-56
Blanchett DG, Green JA, Nara A, Pospisil R, Jarvis RC, Kasmer RJ, Coumot A (see Berlin et al). 1991;49:362-9
Boyle DA, Cyronak MJ, Corder CN. The effect of food on phar- Coyne PE (see Taylor et al). 1991;49:698-700
macokinetics and pharmacodynamics of fenoldopam in class III Craig RM (see Ehrenpreis et al). 1991;49:632-40
heart failure. 1991;49:449-56 Crespo-Laumonnier B (see Berlin et al). 1991;49:362-9
Blauw GJ, van Brummelen P, Doorenbos CJ, van der Velde EA, van Cyronak MJ (see Blanchett et al). 1991;49:449-56
Zwieten PA. The acute and chronic antihypertensive effects of
ketanserin cannot be explained by blockade of vascular serotonin, D
type 2, receptors or 01}-adrenergic receptors. 1991;49:377-84
Dahlqvist R (see Hedman et al). 1991;49:256-62
Danso K (see Shapiro et al). 1991;49:506-14
Dayer P( see Piletta et al). 1991;49:350-4
January, pp. 1-122; February, pp. 123-228; March, pp. 229-346; Debray M (see Sandouk et al). 1991;49:442-8
April, pp. 347-480; May, pp. 481-604; June, pp. 605-720. Dellenbach M (see Schoerlin et al). 1991;49:32-8
CLIN PHARMACOL THER
708 Author index
JUNE 1991
Demotes-Mainard F, Vingon G, Amouretti M, Dumas F, Necciari J, Goodman RP (see Moser et al). 1991;49:322-9
Kieffer G, Begaud B. Pharmacokinetics and protein binding of Got P (see Sandouk et al). 1991;49:442-8
cefpiramide in patients with alcoholic cirrhosis. 1991;49:263-9 Gourley LA (see Moser et al). 1991;49:322-9
Denaro C (see Benowitz et al). 1991;49:270-7 Gram LF (see Clasen et al). 1991;49:624-31
DeSilva J (see Moser et al). 1991;49:322-9 —— (see Skjelbo et al). 1991;49:18-23
Desjardins RE (see Shapiro et al). 1991;49:506-14 Gray HT (see Turgeon et al). 1991;49:488-96
Distlerath LM (see Bauer et al). 1991;49:658-64 Green JA (see Blanchett et al). 1991;49:449-56
Docherty JC, Wilson TW. Effect of indomethacin on arachidonic acid Greenberg HE (see Rapoport et al). 1991;49:394-401
metabolism in human leukocytes stimulated ex vivo. 1991;49:294- Gulino SP (see Ehrenpreis et al). 1991;49:632-40
9 Guttormsen AB (see Ermens et al). 1991;49:385-93
Dolin R (see Knupp et al). 1991;49:523-35
Donati F, Varin F, Ducharme J, Gill SS, Théorét Y, Bevan DR. Phar- H
macokinetics and pharmacodynamics of atracurium obtained with
arterial and venous blood samples. 1991;49:515-22 Hall SD (see Fredrick et al). 1991;49:241-7
Doorenbos CJ (see Blauw et al). 1991;49:377-84 Hallas J (see Skjelbo et al). 1991;49:18-23
Douglas FL (see Martin et al). 1991;49:433-41 Hammarlund-Udenaes M (see von Bahr et al). 1991;49:234-40
Ducharme J (see Donati et al). 1991;49:515-22 Handy T (see Burton et al). 1991;49:685-94
Duchin KL (see Hui et al). 1991;49:457-67 Harrison NJ (see Blum et al). 1991;49:420-5
Dumas F (see Demotes-Mainard et al). 1991;49:263-9 Hasan SS (see Robin et al). 1991;49:581-8
Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharma- Havula P (see Kaila et al). 1991;49:53-8
cokinetics and pharmacodynamics of methylprednisolone in obe- Hedberg A (see von Bahr et al). 1991;49:2.4-40
sity. 1991;49:536-49 Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B,
Olsson M, Schenck-Gustafsson K. Digoxin-verapamil interaction:
reduction of biliary but not renal digoxin clearance in humans.
1991;49:256-62
Eggers H (see Schoerlin et al). 1991;49:32-8 Heishman SJ (see Fudala et al). 1991;49:300-6
Ehrenpreis ED, Gulino SP, Patterson BK, Craig RM, Yokoo H, Atkin- Henningfield JE (see Fudala et al). 1991;49:300-6
son AJ Jr. Kinetics of D-xylose absorption in patients with human Henry EB (see Blum et al). 1991;49:420-5
immunodeficiency virus enteropathy. 1991;49:632-40 Hill DP Jr (see Burton et al). 1991;49:685-94
Eichler H-G (see Bléchl-Daum et al). 1991;49:49-52 Hill MR (see Szefler et al). 1991;49:59-68
Ejima A (see Kaniwa et al). 1991;49:641-7 Hilligoss DM (see Blum et al). 1991;49:420-5
Eliasson AH (see Taylor et al). 1991;49:698-700 Hoevels B (see Schoerlin et al). 1991;49:32-8
Elliott WJ, Karnezis TA, Silverman RA, Geanon J, Tripathi RC, Mur- Hohnloser S (see Zehender et al). 1991;49:78-85
phy MB. Intraocular pressure increases with fenoldopam, but not Hollifield JW (see Moser et al). 1991;49:322-9
nitroprusside, in hypertensive humans. 1991;49:285-93 Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for de-
Ermens AAM, Refsum H, Rupreht J, Spijkers LJM, Guttormsen AB, termination of dextromethorphan metabolic phenotype. 1991;49:
Lindemans J, Ueland PM, Abels J. Monitoring cobalamin inacti- 410-9
vation during nitrous oxide anesthesia by determination of Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N.
homocysteine and folate in plasma and urine. 1991;49:385-93 Pharmacokinetics of fosinopril in patients with various degrees of
renal function. 1991;49:457-67
F Hull RW (see Taylor et al). 1991;49:698-700
Hutabarat RM, Unadkat JD, Sahajwalla C, McNamara S, Ramsey B,
Faich GA. Postmarketing drug surveillance studies. 1991;49:597 (Let-
Smith AL. Disposition of drugs in cystic fibrosis. I. Sul-
ter)
famethoxazole and trimethoprim. 1991;49:402-9
Fee EC (see Kales et al). 1991;49:468-76
Huupponen R (see Kaila et al). 1991;49:53-8
Fiset C (see LeBel and Fiset). 1991;49:596 (Letter reply)
Fitzgerald D (see Salmon et al). 1991;49:589-95
Forbes JA, Beaver WT, Jones KF, Kehm CJ, Smith WK, Gongloff
CM, Zeleznock JR, Smith JW. Effect of caffeine on ibuprofen an-
lisalo E (see Kaila et al). 1991;49:53-8
algesia in postoperative oral surgery pain. 1991;49:674-84 Imazato Y (see Kaniwa et al). 1991;49:641-7
Franceschini G (see Pazzucconi et al). 1991;49:278-84 Iriah J (see Tang et al). 1991;49:648-57
Fredrick MJ, Pound DC, Hall SD, Brater DC. Furosemide absorption
in patients with cirrhosis. 1991;49:241-7 J
Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE. Human phar-
macology and abuse potential of nalmefene. 1991;49:300-6 Jacob P III (see Benowitz et al). 1991;49:270-7
Funck-Brentano C (see Paviou et al). 1991;49:314-21 Jamieson MJ (see Shepherd et al). 1991;49:69-77
—— (see Turgeon et al). 1991;49:488-96 Jarvis RC (see Blanchett et al). 1991;49:449-56
Jenkins R (see Benowitz et al). 1991;49:270-7
G Johnson RE (see Fudala et al). 1991;49:300-6
Jones KF (see Forbes et al). 1991;49:674-84
Gal PS (see Wiest et al). 1991;49:550-7
Jonkman JHG, Sollie FAE, Sauter R, Steinijans VW. The influence of
Galli G (see Pazzucconi et al). 1991;49:278-84 caffeine on the steady-state pharmacokinetics of theophylline.
Gardner MJ (see Blum et al). 1991;49:420-5
1991;49:248-55
Gamer SS (see Wiest et al). 1991;49:618-23
Jusko WJ (see Dunn et al). 1991;49:536-49
Geanon J (see Elliott et al). 1991;49:285-93
—— (see Yamashita et al). 1991;49:558-70
Geibel A (see Zehender et al). 1991;49:78-85
Just H (see Zehender et al). 1991;49:78-85
Gill SS (see Donati et al). 1991;49:515-22
Gillette PC (see Wiest et al). 1991;49:618-23 K
Goldring RM (see Rapoport et al). 1991;49:394-401
Gongloff CM (see Forbes et al). 1991;49:674-84 Kadar D (see Tang et al). 1991;49:648-57
Goodman G (see Meyers et al). 1991;49:307-13 Kaik G (see Bauer et al). 1991;49:658-64
VOLUME 49
Author index 709
NUMBER 6
Kaila T, Huupponen R, Karhuvaara S, Havula P, Scheinin M, lisalo E, Luthra A, Borkowski KR, Carruthers SG. Genetic aspects of variabil-
Salminen L. B-Blocking effects of timolol at low plasma concen- ity in superficial vein responsiveness to norepinephrine. 1991;49:
trations. 1991;49:53-8 355-61
Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee
EC. Rebound insomnia after only brief and intermittent use of rap-
idly eliminated benzodiazapines. 1991;49:468-76
Madsen L( see Clasen et al). 1991;49:624-31
Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the
Malavasi B (see Pazzucconi et al). 1991;49:278-84
enzyme-inducing effect of cigarette smoking. 1991;49:44-8
Manfredi RL (see Kales et al). 1991:49:468-76
(see Tang et al). 1991;49:648-57
Martin LL, Schaffer AV, Piraino A, Linberg L, Singh K, Rakhit A,
Kanee A (see Rieder et al). 1991;49:13-7
Douglas FL. Pharmacokinetics of CGS 12970 and inhibition of
Kaniwa N, Ogata H, Aoyagi N, Ejima A, Takahashi T, Uezono Y, Im-
thromboxane synthesis after oral administration in healthy adults.
azato Y. Effect of food on the bioavailability of cyclandelate from
1991;49:433-41
commercial capsules. 1991;49:641-7
Martin RJ (see Szefler et al). 1991;49:59-68
Kaojarem S, Supmonchai K, Phuapradit P, Mokkhavesa C,
Martin RR (see Knupp et al). 1991;49:523-35
Krittiyanunt S. Effect of steroids on cerebrospinal fluid penetra-
Mayersohn M (see Schoerlin et al). 1991;49:32-8
tion of antituberculous drugs in tuberculous meningitis. 1991;49:
McKenney JM (see Moser et al). 1991;49:322-9
6-12
McLaren C (see Knupp et al). 1991;49:523-35
Karhuvaara S (see Kaila et al). 1991;49:53-8
McNamara S (see Hutabarat et al). 1991;49:402-9
Kamezis TA (see Elliott et al). 1991;49:285-93 Meinertz T (see Zehender et al). 1991;49:78-85
Kasmer RJ (see Bianchett et al). 1991;49:449-56
Meyer PS (see Hou et al). 1991;49:410-9
Kaufman DW (see Kelly et al). 1991;49:330-41 Meyer UA (see Brgsen et al). 1991;49:609-17
Kehm CJ (see Forbes et al). 1991;49:674-84 Meyers FJ, Paradise C, Scudder SA, Goodman G, Konrad M. A phase
Kelly JP, Kaufman DW, Shapirc S. Risks of agranulocytosis and I study including pharmacokinetics of polyethylene glycol conju-
aplastic anemia in relation to the use of cardiovascular drugs: The
gated interleukin-2. 1991;49:307-13
Intemational Agranulocytosis and Aplastic Anemia Study. 1991; Middleton E Jr (see Yamashita et al). 1991;49:558-70
49:330-41
Miller K (see Moser et al). 1991;49:322-9
Kenny M (see Salmon et al). 1991;49:589-95
Misfeldt S (see Clasen et al). 1991;49:624-31
Kieffer G (see Demotes-Mainard et al). 1991;49:263-9 Mokkhavesa C (see Kaojarem et al). 1991;49:6-12
Kirkendall WM (see Moser et al). 1991;49:322-9 Morganroth J (see Moser et al). 1991;49:322-9
Kivist6 KT, Neuvonen PJ. Enhancement of absorption and effect of Movin G (see von Bahr et al). 1991;49:234-40
glipizide by magnesium hydroxide. 1991;49:39-43 Munafo A (see Buclin et al). 1991;49:665-73
Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A. Murphy MB (see Elliott et al). 1991;49:285-93
Absorption studies of the H2-blocker nizatidine (1987;42:5 14-20).
1991;49:255 (Correction)
Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR,
Pittmar KA, Barbhaiya RH. Pharmacokinetics of didanosine in Nafziger AN, Bertino JS Jr. Menstrual cycle and renal clearance.
patients with acquired immunodeficiency syndrome or acquired 1991;49:596 (Letter)
immunodeficiency syndrome-related complex. 1991;49:523-35 Nara A (see Blanchett et al). 1991;49:449-56
Konrad M (see Meyers et al). 1991;49:307-13 Necciari J (see Demotes-Mainard et al). 1991;49:263-9
Kom A (see Bléchl-Daum et al). 1991;49:49-52 Nelson DJ (see Shapiro et al). 1991;49:506-14
Kramer PK (see Hui et al). 1991;49:457-67 Neuvonen PJ (see Kivist6 and Neuvonen). 1991;49:39-43
Kripalani KJ (see Hui et al). 1991;49:457-67 Nilsson B (see Hedman et al). 1991;49:256-62
Noe DA, Kumor K. A pharmacokinetic-pharmacodynamic model of
Krittiyanunt S (see Kaojarem et al). 1991;49:6-12
heart rate during cocaine administration in humans. 1991;49:426-
Kumor K (see Noe and Kumor). 1991;49:426-32
32
Kwan CM (see Shepherd et al). 1991;49:69-77
Nordin C (see von Bahr et al). 1991;49:234-40
L °
Landault C (see Berlin et al). 1991;49:362-9 Ogata H (see Kaniwa et al). 1991;49:641-7
Laska EM, Siegel C, Sunshine A. Onset and duration: measurement Olsson M (see Hedman et al). 1991;49:256-62
and analysis. 1991;49:1-5 (Commentary)
P
Lasseter KC (see Moser et al). 1991;49:322-9
LeBel M, Fiset C. Menstrual cycle and renal clearance. 1991;49:596 Pamplin CL III (see Shapiro et al). 1991;49:506-14
(Letter reply) Panarace G (see Pedrinelli et al). 1991;49:86-93
Legrand JC (see Berlin et al). 1991;49:362-9 Paradise C (see Meyers et al). 1991;49:307-13
Leon AS (see Moser et al). 1991;49:322-9 Patterson BK (see Ehrenpreis et al). 1991;49:632-40
Lichtenstein MJ (see Robin et al). 1991;49:581-8 Pavlou HN, Funck-Brentano C, Lineberry MD, Woosley RL, Roden
Lidén A (see von Bahr et al). 1991;49:234-40 DM. Prospective pharmacokinetically based development of ef-
Linberg L (see Martin et al). 1991;49:433-41 fective infusion regimens for ACC-9358, a new antiarrhythmic
Lindemans J (see Ermens et al). 1991;49:385-93 drug. 1991;49:314-21
Lineberry MD (see Pavlou et al). 1991;49:314-21 —— (see Turgeon et al). 1991;49:488-96
Lippa A (see Bauer et al). 1991;49:658-64 Pazzucconi F, Malavasi B, Galli G, Franceschini G, Calabresi L,
Lippa EA (see Buclin et al). 1991;49:665-73 Sirtori CR. Inhibition of antipyrine metabolism by low-dose con-
Loi CM, Wei X, Vestal RE. Inhibition of theophylline metabolism by traceptives with gestodene and desogestrel. 1991;49:278-84
mexiletine in young male and female nonsmokers. 1991;49:571- Pedrinelli R, Panarace G, Salvetti A. Calcium entry blockade and ad-
80 renergic vascular reactivity in hypertensives: differences between
Ludwig EA (see Dunn et al). 1991;49:536-49 nicardipine and diltiazem. 1991;49:86-93
—— (see Yamashita et al). 1991;49:558-70 Pfefen JP (see Schoerlin et al). 1991;49:32-8
Lunn JA (see Moser et al). 1991;49:322-9 Phuapradit P (see Kaojarem et al). 1991;49:6-12
CLIN PHARMACOL THER
710 Author index ,UNE 1991
Pickle LW (see Hou et al). 1991;49:410-9 Scherrmann JM (see Sandouk et al). 1991;49:442-8
Piletta P, Porchet HC, Dayer P. Central analgesic effect of acetamino- Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M,
phen but not of aspirin. 1991;49:350-4 Pfefen JP. Cimetidine alters the disposition kinetics of the mono-
Pinson JB (see Wiest et al). 1991;49:550-7 amine oxidase-A inhibitor moclobemide. 1991;49:32-8
Piraino A (see Martin et al). 1991;49:433-41 Schuller-Petrovic S (see Bléchl-Daum et al). 1991;49:49-52
Pittman KA (see Knupp et al). 1991;49:523-35 Scoville B. Shifting the burden: restructuring the drug review process.
Porchet HC (see Piletta et al). 1991;49:350-4 1991;49:229-33 (Commentary)
Port RE, Bachert P, Semmler W. Kinetic modeling of in vivo—nuclear Scudder SA (see Meyers et al). 1991;49:307-13
magnetic resonance spectroscopy data: 5-fluorouracil in liver and Semmler W (see Port et al). 1991;49:497-505
liver tumors. 1991;49:497-505 Serrie A (see Sandouk et al). 1991;49:442-8
Pospisil R (see Blanchett et al). 1991;49:449-56 Shapiro S (see Kelly et al). 1991;49:330-41
Pound DC (see Fredrick et al). 1991;49:241-7 Shapiro TA, Were JBO, Danso K, Nelson DJ, Desjardins RE, Pamplin
Prakash C (see Turgeon et al). 1991;49:488-96 CL III. Pharmacokinetics and metabolism of allopurinol riboside.
Pritchett ELC, Wilkinson WE. New drug application strategies for 1991;49:506-14
supraventricular arrhythmias. 1991;49:481-7 Shear NH (see Rieder et al). 1991;49:13-7
Puech AJ (see Berlin et al). 1991;49:362-9 Sheiner LB. A message from the president. 1991;49:96
Purohit D (see Wiest et al). 1991;49:550-7 —— (see Sambol and Sheiner). 1991;49:24-31
Shepherd AMM, Kwan CM, Brodie CL, Jamieson MJ. Determination
Q of a-adrenergic blocking potency. 1991;49:69-77
Shepherd MD (see Burton et al). 1991;49:685-94
Qian L (see Tang et al). 1991;49:648-57
Shiavi RG (see Robin et al). 1991;49:581-8
Shyu WC (see Knupp et al). 1991;49:523-35
Siegel C (see Laska et al). 1991;49:1-5 (Commentary)
Rakhit A (see Martin et al). 1991;49:433-41 Silverman RA (see Elliott et al). 1991;49:285-93
Ramsey B (see Hutabarat et al). 1991;49:402-9 Singh K (see Martin et al). 1991;49:433-41
Ransom JL (see Wiest et al). 1991;49:550-7 Sirtori CR (see Pazzucconi et al). 1991;49:278-84
Rapoport DM, Greenberg HE, Goldring RM. Differing effects of the Sjéqvist F (see von Bahr et al). 1991;49:234-40
anxiolytic agents buspirone and diazepam on control of breathing. Skjelbo E, Brdsen K, Hallas J, Gram LF. The mephenytoin oxidation
1991;49:394-401 polymorphism is partially responsible for the N-demethylation of
Refsum H (see Ermens et al). 1991;49:385-93 imipramine. 1991;49:18-23
Reidenberg MM. Walter Modell, MD, 1977-1990. 1991;49:605 (In Slaughter RL (see Dunn et al). 1991;49:536-49
memoriam) Smith AL (see Hutabarat et al). 1991;49:402-9
——, Goodman H, Erle H, Gray G, Lorenzo B, Leipzig M, Meyer BR, Smith JW (see Forbes et al). 1991;49:674-84
Drayer DE. Hydromorphone levels and pain control in patients Smith WK (see Forbes et al). 1991;49:674-84
with severe chronic pain (1988;44:376-82). 1991;49:313 (Correc- Sollie FAE (see Jonkman et al). 1991;49:248-55
tion) Spielberg SP (see Rieder et al). 1991;49:13-7
Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence Spijkers LJM (see Ermens et al). 1991;49:385-93
of slow acetylator phenotype among patients with sulfonamide hy- Stein WJ (see Moser et al). 1991;49:322-9
persensitivity reactions. 1991;49:13-7 Steinijans VW (see Jonkman et al). 1991;49:248-55
Ring H (see von Bahr et al). 1991;49:234-40 Sunshine A (see Laska et al). 1991;49:1-5 (Commentary)
Robin DW, Hasan SS, Lichtenstein MJ, Shiavi RG, Wood AJJ. Dose- Supmonchai K (see Kaojarem et al). 1991;49:6-12
related effect of triazolam on postural sway. 1991;49:581-8 Surs W (see Szefler et al). 1991;49:59-68
Roden DM (see Paviou et al). 1991;49:314-21 Szefler SJ, Ando R, Cicutto LC, Surs W, Hill MR, Martin RJ. Plasma
—— (see Turgeon et al). 1991;49:488-96 histamine, epinephrine, cortisol, and leukocyte B-adrenergic re-
Ruddy MC (see Moser et al). 1991;49:322-9 ceptors in noctumal asthma. 1991;49:59-68
Rupreht J (see Ermens et al). 1991;49:385-93
T
$s
Sahajwalla C (see Hutabarat et al). 1991;49:402-9 Takahashi T (see Kaniwa et al). 1991;49:641-7
Salminen L (see Kaila et al). 1991;49:53-8 Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a
Salmon P, Fitzgerald D, Kenny M. No effect of famotidine on cardiac metabolic probe: validation of its use for acetylator phenotyping.
performance by noninvasive hemodynamic measurements. 1991; 1991;49:648-57
49:589-95 —— (see Kalow and Tang). 1991;49:44-8
Salvetti A (see Pedrinelli et al). 1991;49:86-93 (see Rieder et al). 1991;49:13-7
Sambhi MP (see Moser et al). 1991;49:322-9 Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamid-
Sambol NC, Sheiner LB. Population dose versus response of betaxolol ine-induced torsade de pointes: safe completion of therapy with in-
and atenolol: a comparison of potency and variability. 1991;49:24- haled pentamidine. 1991;49:698-700
31 Théorét Y (see Donati et al). 1991;49:515-22
Sandouk P, Serrie A, Urtizberea M, Debray M, Got P, Scherrmann Thomas M. Spontaneous adverse drug reaction monitoring program: a
JM. Morphine pharmacokinetics and pain assessment after in- springboard to better physician education in developing countries.
tracerebroventricular administration in patients with terminal can- 1991;49:347-9 (Commentary)
cer. 1991;49:442-8 Till P (see Bauer et al). 1991;49:658-64
Sauter R (see Jonkman et al). 1991;49:248-55 Travers AF. A fatality after antipyrine administration. 1991;49:695-6
Schaffer AV (see Martin et al). 1991;49:433-41 Tripathi RC (see Elliott et al). 1991;49:285-93
Schall S (see Wiest et al). 1991;49:550-7 Trippel DL (see Wiest et al). 1991;49:618-23
Scheinin M (see Kaila et al). 1991;49:53-8 Turgeon J, Funck-Brentano C, Gray HT, Pavlou HN, Prakash C, Blair
Schelling JL (see Buclin et al). 1991;49:665-73 IA, Roden DM. Genetically determined stereoselective excretion
Schenck-Gustafsson K (see Hedman et al). 1991;49:256-62 of encainide in humans and electrophysiologic effects of its en-
Schentag JJ (see Blum et al). 1991;49:420-5 antiomers in canine cardiac Purkinje fibers. 1991;49:488-96
VOLUME 49 Author index 711
NUMBER 6
U Wiest DB, Pinson JB, Gal PS, Brundage RC, Schall S, Ransom JL,
Weaver RL, Purohit D, Brown Y. Population pharmacokinetics of
Ueland PM (see Ermens et al). 1991;49:385-93 intravenous indomethacin in neonates with symptomatic patent
Uezono Y (see Kaniwa et al). 1991;49:641-7 ductus arteriosus. 1991;49:550-7
Unadkat JD (see Hutabarat et al). 1991;49:402-9 ——, Trippel DL, Gillette PC, Garner SS. Pharmacokinetics of es-
Unrtizberea M (see Sandouk et al). 1991;49:442-8 molol in children. 1991;49:618-23
Wilkinson WE (see Pritchett and Wilkinson). 1991;49:481-7
Vv Williams RL (see Moser et al). 1991;49:322-9
Wilson TW (see Docherty and Wilson). 1991;49:294-9
Valentine FT (see Knupp et al). 1991;49:523-35 Wilton JH (see Blum et al). 1991;49:420-5
van Brummelen P (see Blauw et al). 1991;49:377-84 Wolzt M (see Bléchl-Daum et al). 1991;49:49-52
van der Velde EA (see Blauw et al). 1991;49:377-84 Wood AJJ (see Robin et al). 1991;49:581-8
van Melle G (see Buclin et al). 1991;49:665-73 Woosley RL (see Hou et al). 1991;49:410-9
van Zwieten PA (see Blauw et al). 1991;49:377-84 (see Pavlou et al). 1991;49:314-21
Varin F (see Donati et al). 1991;49:515-22 —— (see Taylor et al). 1991;49:698-700
Vasko MR (see Burton et al). 1991;49:685-94
Vela-Bueno A (see Kales et al). 1991;49:468-76 Y
Vestal RE (see Loi et al). 1991;49:571-80
Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of phar-
Vgontzas AN (see Kales et al). 1991;49:468-76
macokinetic and pharmacodynamic interactions between
Vingon G (see Demotes-Mainard et al). 1991;49:263-9
ketoconazole and prednisolone. 1991;49:558-79
von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M,
Yanagawa N (see Hui et al). 1991;49:457-67
Hedberg A, Ring H, Sjéqvist F. Plasma levels of thioridazine and
metabolites are influenced by the debrisoquin hydroxylation phe- Yip J (see Tang et al). 1991;49:648-57
notype. 1991;49:234-40 Yokoo H (see Ehrenpreis et al). 1991;49:632-40
Zz
w
Zawada ET (see Moser et al). 1991;49:322-9
Weaver RL (see Wiest et al). 1991;49:550-7 Zehender M, Meinertz T, Hohnloser S, Geibel A, Just H. Efficacy and
Weber MA (see Moser et al). 1991;49:322-9 tolerance of the new class IB antiarrhythmic barucainide: an intra-
Wei X (see Loi et al). 1991;49:571-80 venous dose-finding study. 1991;49:78-85
Were JBO (see Shapiro et al). 1991;49:506-14 Zeleznock JR (see Forbes et al). 1991;49:674-84
Whalen JJ (see Moser et al). 1991;49:322-9 Zeugin T (see Brgsen et al). 1991;49:609-17
Subject index
B-Blocking effects of timolol at low plasma concentrations (Kaila
et al). 1991;49:53-8
Interaction between oral verapamil and B-blockers during sub-
Abstracts maximal exercise: relevance of ancillary properties (Bailey
Abstracts. 1991;49:123-228
and Carruthers). 1991;49:370-6
ACC-9358
Adverse drug reactions; see Drugs, adverse effects
Prospective pharmacokinetically based development of effective
Agranulocytosis
infusion regimens for ACC-9358, a new antiarrhythmic drug
Risks of agranulocytosis and aplastic anemia in relation to the use
(Pavlou et al). 1991;49:314-21
Acetaminophen of cardiovascular drugs: The International Agranulocytosis
Central analgesic effect of acetaminophen but not of aspirin and Aplastic Anemia Study (Kelly et al). 1991;49:330-41
(Piletta et al). 1991;49:350-4 AIDS; see Acquired immunodeficiency syndrome
Acetylation AIDS-related complex
Caffeine as a metabolic probe: validation of its use for acetylator Pharmacokinetics of didanosine in patients with acquired im-
phenotyping (Tang et al). 1991;49:648-57 munodeficiency syndrome or acquired immunodeficiency syn-
Prominence of slow acetylator phenotype among patients with sul- drome-related complex (Knupp et al). 1991;49:523-35
fonamide hypersensitivity reactions (Rieder et al). 1991;49:13- Aldesleukin
7 Aldesleukin (USAN List No. 325). 1991;49:343
Acetyldigoxin Alentemol hydrobromide
Risks of agranulocytosis and aplastic anemia in relation to the use Alentemol hydrobromide (USAN List No. 325). 1991;49:342
of cardiovascular drugs: The International Agranulocytosis
Allopurinol
and Aplastic Anemia Study (Kelly et al). 1991;49:330-41
Pharmacokinetics and metabolism of allopurinol riboside (Shapiro
Acetylsalicylic acid; see Aspirin
et al). 1991;49:506-14
Acquired immunodeficiency syndrome
Kinetics of D-xylose absorption in patients with human im- Alpha adrenergic receptor antagonist; see Adrenergic alpha re-
munodeficiency virus enteropathy (Ehrenpreis et al). 1991;49: ceptor agonists
632-40 Alpha adrenergic receptors; see Receptors, adrenergic, alpha
Pharmacokinetics of didanosine in patients with acquired im- Alpha-blockers; see Adrenergic alpha receptor blockaders
munodeficiency syndrome or acquired immunodeficiency syn- American Society for Clinical Pharmacology and Therapeutics
drome-related complex (Knupp et al). 1991;49:523-35 Abstracts. 1991;49:123-228
Adenosine cyclic monvuphosphate Future meeting dates and sites of the ASCPT. 1991;49:702
Plasma histamine, epinephrine, cortisol, and leukocyte B-adrener- Meeting program. 1991;49:97-122
gic receptors in noctumal asthma (Szefler et al). 1991;49:59-
A message from the president (Sheiner). 1991;49:96
68
Notes. 1991;49:598-601, 701-2
Administration, inhalation
Pentamidine-induced torsade de pointes: safe completion of ther- Aminoglycosides
apy with inhaled pentamidine (Taylor et al). 1991;49:698-700 A controlled trial of the cost benefit of computerized bayesian
aminoglycoside administration (Burton et al). 1991;49:685-94
Administration, intracerebroventricular
Morphine pharmacokinetics and pain assessment after in- Analgesia
tracerebroventricular administration in patients with terminal Central analgesic effect of acetaminophen but not of aspirin
cancer (Sandouk et al). 1991;49:442-8 (Piletta et al). 1991;49:350-4
Adozelesin Effect of caffeine on ibuprofen analgesia in postoperative oral sur-
Adozelesin (USAN List No. 326). 1991;49:479 gery pain (Forbes et al). 1991;49:674-84
Adrenergic alpha receptor agonists Anemia, aplastic
The 2-adrenergic receptor antagonist yohimbine inhibits epi- Risks of agranulocytosis and aplastic anemia in relation to the use
nephrine-induced platelet aggregation in healthy subjects (Ber- of cardiovascular drugs: The International Agranulocytosis
lin et al). 1991;49:362-9 and Aplastic Anemia Study (Kelly et al). 1991;49:330-41
Adrenergic alpha receptor blockaders Anesthesia
Determination of 0-adrenergic blocking potency (Shepherd et al).
Monitoring cobalamin inactivation during nitrous oxide anesthesia
1991;49:69-77
by determination of homocysteine and folate in plasma and
Adrenergic beta receptor blockaders
urine (Ermens et al). 1991;49:385-93
Assessment of systemic effects of different ophthalmic B-blockers
Angiotensin-converting enzyme inhibitors
in healthy volunteers (Bauer et al). 1991;49:658-64
The effects of benazepril, a new angiotensin-converting enzyme
inhibitor, in mild to moderate essential hypertension: a multi-
center study (Moser et al). 1991;49:322-9
January, pp. 1-122; February, pp. 123-228; March, pp. 229-346; Pharmacokinetics of fosinopril in patients with various degrees of
April, pp. 347-480; May, pp. 481-604; June, pp. 605-720. renal function (Hui et al). 1991;49:457-67
712
VOLUME 49 Subject index 713
NUMBER 6
Anti-arrhythmia agents Atracurium
Efficacy and tolerance of the new class IB antiarrhythmic Pharmacokinetics and pharmacodynamics of atracurium obtained
barucainide: an intravenous dose-finding study (Zehender et with arterial and venous blood samples (Donati et al). 1991;49:
al). 1991;49:78-85 515-22
New drug application strategies for supraventricular arrhythmias Atropine
(Pritchett and Wilkinson). 1991;49:481-7 Determination of a-adrenergic blocking potency (Shepherd et al).
Prospective pharmacokinetically based development of effective 1991;49:6° 77
infusion regimens for ACC-9358, a new antiarrhythmic drug
(Pavlou et al). 1991;49:314-21
Antihypertensive agents
Barucainide
The acute and chronic antihypertensive effects of ketanserin can-
Efficacy and tolerance of the new class IB antiarrhythmic
not be explained by blockade of vascular serotonin, type 2, re-
barucainide: an intravenous dose-finding study (Zehender et
ceptors or 0t)-adrenergic receptors (Blauw et al). 1991;49: al). 1991;49:78-85
377-84
Bayes theorem
Calcium entry blockade and adrenergic vascular reactivity in hy- A controlled trial of the cost benefit of computerized bayesian
pertensives: differences between nicardipine and diltiazem aminoglycoside administration (Burton et al). 1991;49:685-94
(Pedrinelli et al). 1991;49:86-93 Benazepril
The effects of benazepril, a new angiotensin-converting enzyme The effects of benazepril, a new angiotensin-converting enzyme
inhibitor, in mild to moderate essential hypertension: a multi- inhibitor, in mild to moderate essential hypertension: a multi-
center study (Moser et al). 1991;49:322-9 center study (Moser et al). 1991;49:322-9
Intraocular pressure increases with fenoldopam, but not Benzodiazepines
nitroprusside, in hypertensive humans (Elliott et al). 1991;49: Dose-related effect of triazolam on postural sway (Robin et al).
285-93 1991;49:581-8
Pharmacokinetics of esmolol in children (Wiest et al). 1991;49: Rebound insomnia after only brief and intermittent use of rapidly
618-23 eliminated benzodiazapines (Kales et al). 1991;49:468-76
Population dose versus response of betaxolol and atenolol: a com- Beta adrenergic receptors; see Receptors, adrenergic, beta
parison of potency and variability (Sambol and Sheiner). 1991; Beta-blockers, see Adrenergic beta receptor blockaders
49:24-31 Betaxolol
Antipyrine Assessment of systemic effects of different ophthalmic B-blockers
A fatality after antipyrine administration (Travers). 1991;49:695-6 in healthy volunteers (Bauer et al). 1991;49:658-64
Inhibition of antipyrine metabolism by low-dose contraceptives Population dose versus response of betaxolol and atenolol: a com-
with gestodene and desogestrel (Pazzucconi et al). 1991;49: parison of potency and variability (Sambol and Sheiner). 1991;
278-84 49:24-31
Antitubercular agents Bidisomide
Bidisomide (USAN List No. 325). 1991;49:346
Effect of steroids on cerebrospinal fluid penetration of antitubercu-
Biological availability
lous drugs in tuberculous meningitis (Kaojarem et al).
Effect of food on the bioavailability of cyclandelate from commer-
1991;49:6-12
cial capsules (Kaniwa et al). 1991;49:641-7
Anxiolytic agents; see Tranquilizing agents, minor
Blood pressure
Aplastic anemia; see Anemia, aplastic
Determination of a-adrenergic blocking potency (Shepherd et al).
Aprindine 1991;49:69-77
Risks of agranulocytosis and aplastic anemia in relation to the use Blood vessels
of cardiovascular drugs: The International Agranulocytosis Calcium entry blockade and adrenergic vascular reactivity in hy-
and Aplastic Anemia Study (Kelly et al). 1991;49:330-41 pertensives: differences between nicardipine and diltiazem
Arachidonic acids; see Eicosanoic acids (Pedrinelli et al). 1991;49:86-93
Arrhythmia Breathing; see Respiration
Efficacy and tolerance of the new class IB antiarrhythmic Buspirone
barucainide: an intravenous dose-finding study (Zehender et Differing effects of the anxiolytic agents buspirone and diazepam
al). 1991;49:78-85 on control of breathing (Rapoport et al). 1991;49:394-401
New drug application strategies for supraventricular arrhythmias
(Pritchett and Wilkinson). 1991;49:481-7 c
Pharmacokinetics of esmolol in children (Wiest et al). 1991;49:
618-23 Caffeine
Caffeine as a metabolic probe: exploration of the enzyme-inducing
Arteries
effect of cigarette smoking (Kalow and Tang). 1991;49:44-8
Pharmacokinetics and pharmacodynamics of atracurium obtained
Caffeine as a metabolic probe: validation of its use for acetylator
with arterial and venous blood samples (Donati et al). 1991;49: phenotyping (Tang et al). 1991;49:648-57
515-22
Effect of caffeine on ibuprofen analgesia in postoperative oral sur-
Aspiria gery pain (Forbes et al). 1991;49:674-84
Central analgesic effect of acetaminophen but not of aspirin The influence of caffeine on the steady-state pharmacokinetics of
(Piletta et al). 1991;49:350-4 theophylline (Jonkman et al). 1991;49:248-55
Asthma Calcium channel blockers
Plasma histamine, epinephrine, cortisol, and leukocyte B-adrener- Calcium entry blockade and adrenergic vascular reactivity in hy-
gic receptors in noctumal asthma (Szefler et al). 1991;49:59- pertensives: differences between nicardipine and diltiazem
68 (Pedrinelli et al). 1991;49:86-93
Atenolol Caldiamide sodium
Population dose versus response of betaxolol and atenolol: a com- Caldiamide sodium (USAN List No. 327). 1991;49:602
parison of potency and variability (Sambol and Sheiner). 1991; Calteridol calcium
49:24-31 Calteridol calcium (USAN List No. 327). 1991;49:603
714 Subject index CLIN PHARMACOL THER
JUNE 1991
Cancer; see Neoplasms Cost benefit analysis
Carbonic anhydrase inhibitors A controlled trial of the cost benefit of computerized bayesian
Absence of metabolic effects of the topical carbonic anhydrase in- aminoglycoside administration (Burton et al). 1991;49:685-94
hibitors MK-927 and sezolamide during two-week ocular ad- Course; see Education
ministration to normal subjects (Buclin et al). 1991;49:665-73 Cyclandelate
Cardiovascular agents Effect of food on the bioavailability of cyclandelate from commer-
Risks of agranulocytosis and aplastic anemia in relation to the use cial capsules (Kaniwa et al). 1991;49:641-7
of cardiovascular drugs: The International Agranulocytosis Cyclic adenosine monophosphate; see Adenosine cyclic mono-
and Aplastic Anemia Study (Kelly et al). 1991;49:330-41 phosphate
Cefetecol Cystic fibrosis
Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and
Cefetecol (USAN List No. 324). 1991;49:95
trimethoprim (Hutabarat et al). 1991;49:402-9
Cefpiramide
Cytochrome P-450
Pharmacokinetics and protein binding of cefpiramide in patients
Caffeine as a metabolic probe: exploration of the enzyme-inducing
with alcoholic cirrhosis (Demotes-Mainard et al). 1991;49:
effect of cigarette smoking (Kalow and Tang). 1991;49:44-8
263-9
Cerebrospinal fluid
Effect of steroids on cerebrospinal fluid penetration of antitubercu-
lous drugs in tuberculous meningitis (Kaojarem et al). 1991; Death
49:6-12 A fatality after antipyrine administration (Travers). 1991;49:695-6
Morphine pharmacokinetics and pain assessment after in- Debrisoquin
tracerebroventricular administration in patients with terminal Plasma levels of thioridazine and metabolites are influenced by the
cancer (Sandouk et al). 1991;49:442-8 debrisoquin hydroxylation phenotype (von Bahr et al). 1991;
CGS 12970 49:234-40
Pharmacokinetics of CGS 12970 and inhibition of thromboxane Role of P4S50IID6, the target of the sparteine-debrisoquin oxida-
synthesis after oral administration in healthy adults (Martin et tion polymorphism, in the metabolism of imipramine (Brdsen
al). 1991;49:433-41 et al). 1991;49:609-17
Child N-Demethylation; see Oxidoreductases, N-demethylating
Desogestrel
Pharmacokinetics of esmolol in children (Wiest et al). 1991;49:
Inhibition of antipyrine metabolism by low-dose contraceptives
618-23
with gestodene and desogestrel (Pazzucconi et al). 1991;49:
Population pharmacokinetics of intravenous indomethacin in neo-
278-84
nates with symptomatic patent ductus arteriosus (Wiest et al).
Developing countries
1991;49:550-7
Spontaneous adverse drug reaction monitoring program: a spring-
Cigarette smoking; see Smoking
board to better physician education in developing countries
Cimetidine
(Thomas). 1991;49:347-9 (Commentary)
Cimetidine alters the disposition kinetics of the monoamine oxi- Dextromethorphan
dase-A inhibitor moclobemide (Schoerlin et al). 1991;49:32-8 Salivary analysis for determination of dextromethorphan meta-
Cinepazide bolic phenotype (Hou et al). 1991;49:410-9
Risks of agranulocytosis and aplastic anemia in relation to the use Diarrhea
of cardiovascular drugs: The International Agranulocytosis Kinetics of D-xylose absorption in patients with human im-
and Aplastic Anemia Study (Kelly et al). 1991;49:330-41 munodeficiency virus enteropathy (Ehrenpreis et al). 1991;49:
Cirrhosis, alcoholic; see Liver cirrhosis, alcoholic 632-40
Clinical Pharmacology Rounds Diazepam
Note from the editor. 1991;49:697 Differing effects of the anxiolytic agents buspirone and diazepam
Clinical trials on control of breathing (Rapoport et al). 1991;49:394-401
Shifting the burden: restructuring the drug review process (Sco- Didanosine
ville). 1991;49:229-33 (Commentary) Pharmacokinetics of didanosine in patients with acquired im-
Cobalamin munodeficiency syndrome or acquired immunodeficiency syn-
Monitoring cobalamin inactivation during nitrous oxide anesthesia drome-related complex (Knupp et al). 1991;49:523-35
by determination of homocysteine and folate in plasma and Digoxin
urine (Ermens et al). 1991;49:385-93 Digoxin-verapamil interaction: reduction of biliary but not renal
Cocaine digoxin clearance in humans (Hedman et al). 1991;49:256-62
Risks of agranulocytosis and aplastic anemia in relation to the use
A pharmacokinetic-pharmacodynamic model of heart rate during
of cardiovascular drugs: The International Agranulocytosis
cocaine administration in humans (Noe and Kumor). 1991;49:
426-32 and Aplastic Anemia Study (Kelly et al). 1991;49:330-41
Diltiazem
Commentaries
Calcium entry blockade and adrenergic vascular reactivity in hy-
Commentaries. 1991;49:1-5, 229-33, 347-9, 606-8
pertensives: differences between nicardipine and diltiazem
Contraceptives, oral
(Pedrinelli et al). 1991;49:86-93
Inhibition of antipyrine metabolism by low-dose contraceptives Dipyridamole
with gestodene and desogestrel (Pazzucconi et al). 1991;49: Risks of agranulocytosis and aplastic anemia in relation to the use
278-84 of cardiovascular drugs: The International Agranulocytosis
Corrections and Aplastic Anemia Study (Kelly et al). 1991;49:330-41
Absorption studies of the H2-blocker nizatidine (Knadler et al) Dose-response relationship, drug
(1987;42:514-20). 1991;49:255 Population dose versus response of betaxolol and atenolol: a com-
Hydromorphone levels and pain control in patients with severe parison of potency and variability (Sambol and Sheiner). 1991;
chronic pain (Reidenberg et al) (1988;44:376-82). 1991;49: 49:24-31
313 Doxofylline
Cortisol, see Hydrocortisone Doxofylline (USAN List No. 327). 1991;49:604